Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
October, 2026
October 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Luis Oliverio Ambriz Garcia: Key Insights Into Myeloproliferative Neoplasms From the 2026 NEJM Review
Luis Oliverio Ambriz Garcia/X
Aug 23, 2026, 16:01

Luis Oliverio Ambriz Garcia: Key Insights Into Myeloproliferative Neoplasms From the 2026 NEJM Review

Luis Oliverio Ambriz Garcia, Doctor, Specialist in Internal Medicine at HRAEB, Chief Executive Officer of Memodi, shared a post on X about a recent article by Isabelle Plo and William Vainchenker, published in NEJM, adding:

“Myeloproliferative Neoplasms, Review in New England Journal of Medicine (2026).

Key Points:

  • JAK2, CALR, and MPL cause more than 90% of cases. Persistent thrombocytosis or erythrocytosis without a secondary cause: request molecular panel.
  • The mutation precedes the disease by decades. A positive JAK2 does not equal a diagnosis.
  • Thrombosis is driven by inflammation, not the count. In ET, stratify with IPSET Score, not with platelets.
  • Polycythemia Vera: Pegylated interferon alfa is superior to hydroxyurea in preventing thrombosis.
  • No current treatment eradicates the clone. JAK inhibitors improve symptoms; the survival benefit is modest. Anti-mutated CALR therapies remain in early phase.
  • Transformation to AML: 0.7–3.8% in ET vs 20.6% in primary myelofibrosis. Once transformed, median survival 3–5 months.”

Title: Myeloproliferative Neoplasms

Authors: Isabelle Plo, William Vainchenker

Luis Oliverio Ambriz Garcia

Stay updated on all scientific advances Hemostasis Today.

(inflammation Blood CALR Erythrocytosis ET Health Hematology Hemostasis Hemostasis News Hemostasis Today Isabelle Plo JAK Inhibitors JAK2 Luis Oliverio Ambriz Garcia Medicine MPL myeloproliferative neoplasms NEJM New England Journal of Medicine platelets polycythemia vera Thrombocytosis thrombosis William Vainchenker
NewsFeed